医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Administration

Otsuka Medical Devices and ReCor Medical Announce Submission of Application for Pre-Market Approval of the Paradise™ Ultrasound Renal Denervation (uRDN) System to the U.S. Food and Drug Administration

Otsuka Medical Devices and ReCor Medical Announce Submission of Application for Pre-Market Approval of the Paradise™ Ultrasound Renal Denervation (uRDN) System to the U.S. Food and Drug Administration

ヘルスケア医療機器臨床試験　 TimeLine: Administration Food and Drug Ultrasound Renal Denervation uRDN

2022年11月30日

Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration

Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration

バイオテクノロジーヘルスケアヘルス一般感染症製薬　 TimeLine: Administration BLA Granted Priority Review TAK-003 Takeda’s Biologics License Application

2022年11月23日

CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration

CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: Administration Application NDA ORD Registration

2022年03月29日

Dr. Reddy’s Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)

Dr. Reddy’s Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)

バイオテクノロジーヘルスケア製薬　 TimeLine: Administration Food and Drug Reddy's Laboratories Announces Approval for Lenalidomide Capsules USFDA

2021年10月19日

SCC Soft Computer’s Blood Bank Product Receives 510(k) Clearance from the U.S. Food and Drug Administration

その他ヘルスヘルスケアヘルス一般医療用品医療管理　 TimeLine: Administration Food and Drug SCC Soft Computer’s Blood Bank Product Receives

2021年01月20日

Astex Pharmaceuticals Announces U.S. Food and Drug Administration (FDA) Acceptance for Review of an NDA for the Combination Oral Hypomethylating Agent Cedazuridine and Decitabine (ASTX727 or oral C-DEC), for the Treatment of MDS and CMML

Astex Pharmaceuticals Announces U.S. Food and Drug Administration (FDA) Acceptance for Review of an NDA for the Combination Oral Hypomethylating Agent Cedazuridine and Decitabine (ASTX727 or oral C-DEC), for the Treatment of MDS and CMML

ヘルスケア腫瘍学臨床試験製薬　 TimeLine: Administration Astex Pharmaceuticals Announces ASTX727 or oral C-DEC FDA Food and Drug

2020年02月12日